Orphan designation: Eplontersen Treatment of transthyretin-mediated amyloidosis, 13/10/2023 Withdrawn | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 3 December 2024 - 14:12

Orphan designation: Eplontersen Treatment of transthyretin-mediated amyloidosis, 13/10/2023 Withdrawn

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2828

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters